Takayuki Ueno

38PUBLICATIONS
95CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tissue engineeringModels of care and place of birthPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Sep 02, 2026
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.

|Jul 22, 2026
Super homotypic targeting by surface engineering of extracellular vesicles.

|Dec 05, 2025
Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy.

Meiko Nishimura, Takayuki Kobayashi, Yosuke Aoyama

|Oct 24, 2025
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey.

Masahiro Takada, Shigehira Saji, Takayuki Ueno

|Sep 01, 2025
Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.

Takayuki Ueno, Louis W C Chow, Wonshik Han

|Feb 19, 2025
Prognostic Impact of Stimulator of Interferon Genes Expression in Triple Negative Breast Cancer.

Tetsuyo Maeda, Makiko Ono, Tomo Osako

Pageof 7

Frequent Collaborators

7 joint publications

Tomo Osako

6 joint publications

Norikazu Masuda

5 joint publications

Toshimi Takano

5 joint publications

Reo Maruyama